CS236549B1 - Piperazinoalkanoles of dibenzo (b,e)thiepine series and their salts with maleic acid - Google Patents
Piperazinoalkanoles of dibenzo (b,e)thiepine series and their salts with maleic acid Download PDFInfo
- Publication number
- CS236549B1 CS236549B1 CS76484A CS76484A CS236549B1 CS 236549 B1 CS236549 B1 CS 236549B1 CS 76484 A CS76484 A CS 76484A CS 76484 A CS76484 A CS 76484A CS 236549 B1 CS236549 B1 CS 236549B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- acid
- maleic acid
- thiepine
- salts
- dibenzo
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 6
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 title claims abstract description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title abstract description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title abstract description 11
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 title abstract description 8
- 239000011976 maleic acid Substances 0.000 title abstract description 8
- 150000003551 thiepines Chemical class 0.000 title abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 229910052801 chlorine Chemical group 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 238000002425 crystallisation Methods 0.000 abstract description 5
- 230000008025 crystallization Effects 0.000 abstract description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract description 4
- 229940071870 hydroiodic acid Drugs 0.000 abstract description 4
- 208000005392 Spasm Diseases 0.000 abstract description 3
- 208000007101 Muscle Cramp Diseases 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000001387 anti-histamine Effects 0.000 abstract description 2
- 239000000739 antihistaminic agent Substances 0.000 abstract description 2
- 238000009835 boiling Methods 0.000 abstract description 2
- 230000003170 musculotropic effect Effects 0.000 abstract description 2
- 230000002048 spasmolytic effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000002688 maleic acid derivatives Chemical class 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000003610 charcoal Substances 0.000 description 5
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 2
- -1 3-bromopropyl Chemical group 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002689 maleic acids Chemical class 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- CQVKMVQRSNNAGO-UHFFFAOYSA-N 2-[4-formyl-3-methyl-n-(2-methylsulfonyloxyethyl)anilino]ethyl methanesulfonate Chemical compound CC1=CC(N(CCOS(C)(=O)=O)CCOS(C)(=O)=O)=CC=C1C=O CQVKMVQRSNNAGO-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Vynález spadá do oboru synthetických léčiv. Jeho předmětem jsou piperazinoalkanoly dibenzo(b, e)thiepinové řady obecného vzorce I, ve kterém R je atom vodíku nebo atom chloru, a jejich soli s kyselinou maleinovou. Látky podle vynálezu a jejich maleináty se vyznačují antihistaminovou a muskulotropně spasmolytickou účinností, takže mohou být používány jako léčiva pro likvidaci příznaků alergických chorob a dále jako léčiva proti bolestivým svalovým spasmům. Jsou přístupné redukcí příslušných nenasycených piperezinoalkanolů (dvojná vazbě mezi skeletem a prvním článkem pobočného řetězce), s výhodou . kyselinou jodovodíkovou ve vroucí kyselině octové za přítomnosti červeného fosforu. Surové olejovité base se převádějí neutralisací kyselinou maleinovou na krystalické maleináty a v této formě se čistí krystalizací.The invention is within the scope of synthetic drugs. Its subject matter is piperazinoalkanols dibenzo (b, e) thiepine series general formula I, wherein R is hydrogen or chloro, and salts thereof with maleic acid. Compounds of the invention and their maleates are characterized by antihistaminic and musculotropic spasmolytic activity, so can be used as medicines for the elimination of symptoms of allergic diseases and further as painkillers muscle spasm. They are accessible by reduction the corresponding unsaturated piperezinoalkanols (double bond between skeleton and first branch chain), preferably. hydroiodic acid in boiling acid acetic acid in the presence of red phosphorus. The crude oily bases are converted by neutralization maleic acid to crystalline maleate and in this form are purified by crystallization.
Description
Vynález ee týká nových piperazinoalkanolů dibenzo(b,e)thiepinové řady obecného vzorce I,The present invention relates to novel piperazinoalkanols of the dibenzo (b, e) thiepine series of formula I,
(ch2)3n^nch2ch2oh ve kterém R je atom vodíku nebo atom chloru a jejich solí s kyselinou maleinovou.(CH 2 ) 3 CH 2 CH 2 OH wherein R is a hydrogen atom or a chlorine atom and their maleic acid salts.
Látky vzorce 1 podle vynálezu a jejich soli s kyselinou maleinovou se vyznačují antihistaminovou a muskulotropní spasmolytickou účinností a mohou být použity jako léčiva pro likvidaci příznaků alergických chorob a dále jako léčiva proti bolestivým svalovým spasmům. Při intravenosním podání je jejich účinek provázen krátkodobým poklesem krevního tlaku a účinkem adrenolytickým. Vyšší dávky způsobují krátkodobý centrální útlum a ataxii. Farmakodynamické účinky lze prokázat na pokusných zvířatech, jakož i na jejich isolovaných orgánech. Příkladem látky podle vynálezu je 1“(3-/6,11-dihydrodibenao(b,e)thiepin-11-yl/propyl)-4-(2-hydroxyethyl)piperazin (I, R = H), který byl testován ve formě bis(hydrogenmaleinátu). Jeho akutní toxicita u myší při intravenosním podání, LDj0 = 70 mg/kg.The compounds of the formula I according to the invention and their salts with maleic acid are characterized by antihistamine and musculotropic spasmolytic activity and can be used as medicaments for controlling the symptoms of allergic diseases and also as medicaments against painful muscular spasms. When administered intravenously, their effect is accompanied by a short-term decrease in blood pressure and an adrenolytic effect. Higher doses cause short-term central depression and ataxia. Pharmacodynamic effects can be demonstrated on the test animals as well as on their isolated organs. An example of a compound of the invention is 1 '(3- / 6,11-dihydrodibenao (b, e) thiepin-11-yl / propyl) -4- (2-hydroxyethyl) piperazine (I, R = H) which has been tested in in the form of bis (hydrogen maleate). Its acute toxicity in mice by intravenous administration, LDj 0 = 70 mg / kg.
V subkutánní dávce 5 mg/kg látka chrání 50 % morčat v pokuse před smrtícím účinkem dávky 5 mg/kg histaminu, podaného intrajugulárně. V koncentracích 1 až 10jug/ml snižuje na 50 % spasmy isolovaného krysího duodenu, vyvolané standardní koncentrací chloridu barnetého, V intravenosní dávce 14 mg/kg snižuje krátkodobě krevní tlak u normotesivních krys a snižuje presorickou odpovšč po standardní dávce adrenalinu na méně než 50 % kontrolní hodnoty. V dávkách vyšších než ,4 mg/kg i.v. vyvolává u myší ataxii a na 30 min sníženou lokomotorickou aktivitu.At a subcutaneous dose of 5 mg / kg, the substance protects 50% of guinea pigs in the experiment from the lethal effect of a 5 mg / kg dose of histamine administered intra -ugularly. At concentrations of 1 to 10µg / ml it reduces to 50% the spasms of isolated rat duodenum induced by standard barium chloride concentration. values. At doses higher than 4 mg / kg i.v. induces ataxia in mice and reduced locomotor activity for 30 min.
Látky podle vynálezu vzorce 1 jsou přístupné redukcí příslušných nenasycených piperazinoalkanolů obecného vzorce 11,The compounds of the invention of formula 1 are accessible by reducing the corresponding unsaturated piperazinoalkanols of formula 11,
(II), ve kterém R značí totéž jako ve vzorci 1. K redukci se s výhodou použije kyselina jodovodíková ve vroucí kyselině octová za přítomnosti červeného fosforu. Vzniklé olejovité base vzorce I se přečistí buč chromatografii nebo krystalisací ve formě soli s kyselinou maleinovou, které se získají neutralisací surových basi touto kyselinou. Výchozí látky vzorce II jsou zčásti známá, zčásti nové. Látka 11, R = H, byla popsána (Holand.pat. přihl. 64/7758; Fr.pat. 88 751, 3.dodatek k pat. 1 449 569), avšak vzhledem k tomu, že je v citované literatuře jen chudě charakterizována, je její způsob přípravy popsán v příkladu.(II), wherein R is the same as in Formula 1. For the reduction, hydroiodic acid in boiling acetic acid in the presence of red phosphorus is preferably used. The resulting oily bases of formula (I) are purified either by chromatography or by crystallization in the form of a maleic acid salt, obtained by neutralizing the crude bases with this acid. The starting materials of the formula II are partly known, partly new. Substance 11, R = H, has been described (Dutch Pat. Appl. 64/7758; Fr.pat. 88 751, 3rd Amendment to Pat. 1,449,569), but is poor in the literature cited. characterized, its method of preparation is described in the example.
Látka II, R = Cl, je nová a způsob jeji přípravy je rovněž popsán v příkladu.Compound II, R = Cl, is novel and its preparation is also described in the example.
Všechny nové látky ve vynálezu popsané - a to i konečné produkty i meziprddukty - byly z hlediska identity zajištěny analyticky i spektrálně. Dále uvedené příklady představuji jen ilustraci preparativních metod, kterých lze k synthese látek podle vynálezu použit; není jejich účelem popsat všechny možné preparativní způsoby.All of the novel compounds described in the invention - both end products and intermediate products - were analytically and spectrally assured. The following examples are merely illustrative of the preparative methods that can be used to synthesize the compounds of the invention; it is not intended to describe all possible preparative methods.
Příklad 1Example 1
1-(3-/6,11-Dihydrodibenzo(b,e)thiepin-11-yl/propyl)-4-(2-hydroxyethyl)piperazin1- (3- / 6,11-Dihydrodibenzo (b, e) thiepin-11-yl / propyl) -4- (2-hydroxyethyl) piperazine
Směs 5,0 g (E) —1-(3-/6,1 1-dih.ydrodibenzo(b,e) thiepin-11-yliden/propyl-4-(2-hydroxyethyl) oiperazinu, 15 ml kyseliny octové, 5 ml 55® kyseliny jodovodíkové a 2,0 g červeného fosforu se vaří 5 hodin pod zpětným chladičem. Po ochlazení se směs zfiltruje, filtrát se zředí vodou a extrahuje se benzenem. Extrakt se promyje vodou, roztokem uhličitanu sodného a znovu vodou, vysuší se uhličitanem draselným a odpaří za sníženého tlaku. Nehomogenní zbytek se rozpustí v 25 ml ethanolu a k horkému roztoku se přidá roztok 3,0 g kyseliny maleinové v 15 ml ethanolu. Po stáni přes noo se vyloučený bis(hydrogenmaleinét) odsaje a vyčistí krystalisací z ethanolu; 2,4 g (30 %), t.tí.145 až 146,5 °C.A mixture of 5.0 g of (E) -1- (3- / 6,1 1-dihydrodibenzo (b, e) thiepin-11-ylidene) propyl-4- (2-hydroxyethyl) oiperazine, 15 ml of acetic acid, 5 ml of 55 ® hydroiodic acid and 2.0 g of red phosphorus were refluxed for 5 hours, after cooling, the mixture was filtered, the filtrate was diluted with water and extracted with benzene, washed with water, sodium carbonate solution and water again, dried The inhomogeneous residue is dissolved in 25 ml of ethanol and a solution of 3.0 g of maleic acid in 15 ml of ethanol is added to the hot solution, and after standing overnight, the precipitated bis (hydrogen maleate) is filtered off with suction and purified by crystallization from ethanol; 2.4 g (30%), m.p. 145-146.5 ° C.
Výchozí nenasycený aminoalkohol byl sice v literatuře popsán (citováno),, avšak při jeho přípravě je lépe postupovat dále uvedeným způsobem:Although the initial unsaturated amino alcohol has been described (cited) in the literature, it is better to proceed as follows:
Směs 25,0 g (E)-11-(3-brompropyliden)-6,11-dihydrodibenzo(b,e)thiepinu (Rajšner M. et al., Gollect. Czech. Chem. Commun. 44. 2536, 1979). 34,0 g 1-(2-hydroxyethyl)piperazinu a 65 ml chloroformu se míchá a vaří 3 h pod zpětným chladičem. Směs se zředí 100 ml chloroformu, zfiltruje se s aktivním uhlím, filtrát se promyje vodou a base se z něj vyextrahují třepáním do roztoku 25 ml kyseliny chlorovodíkové ve 175 ml vody. Vodná vrstva se opět zfiltruje s aktivním uhlím, filtrát se zalkalizuje vodným amoniakem a produkt se extrahuje dichlormethanem. Extrakt se vysuší uhličitanem draselným a odpaří. Olejovitý zbytek, který představuje surový (E)-1-(3-/6,11-dihydrodibenzo(b,e)thiepin-11-yliden/propyl) -4-(2-hydroxyethyl)piperazin, se rozpustí ve 150 ml ethanolu a roztok se neutralisuje pomocí 16,8 g kyseliny maleinové v 60 ml ethanolu. Stáním a ochlazením vykrystaluje 28,2 g (61 %) bis(hydrógenmaleinátu) tajícího při 154 až 155 °C. Analytický vzorek se získá rekrystalizací z ethanolu, t.t. 155 až 156 °C. Čistá olejovitá base se připraví v teoretickém výtěžku rozkladem této soli vodným amoniakem, extrakcí etherem a odpařením extraktu.A mixture of 25.0 g of (E) -11- (3-bromopropyl) -6,11-dihydrodibenzo (b, e) thiepine (Rajsner M. et al., Gollect. Czech. Chem. Commun. 44. 2536, 1979) . 34.0 g of 1- (2-hydroxyethyl) piperazine and 65 ml of chloroform are stirred and refluxed for 3 hours. The mixture is diluted with 100 ml of chloroform, filtered with charcoal, the filtrate is washed with water and the bases are extracted by shaking into a solution of 25 ml of hydrochloric acid in 175 ml of water. The aqueous layer was again filtered with charcoal, the filtrate basified with aqueous ammonia, and the product was extracted with dichloromethane. The extract was dried over potassium carbonate and evaporated. The oily residue, which is crude (E) -1- (3- / 6,11-dihydrodibenzo (b, e) thiepin-11-ylidene / propyl) -4- (2-hydroxyethyl) piperazine, is dissolved in 150 ml of ethanol. and the solution was neutralized with 16.8 g of maleic acid in 60 ml of ethanol. On standing and cooling, 28.2 g (61%) of bis (hydrogenic maleate) melting at 154-155 ° C crystallized. An analytical sample was obtained by recrystallization from ethanol, m.p. Mp 155-156 ° C. Pure oily base was prepared in theoretical yield by decomposition of this salt with aqueous ammonia, extraction with ether and evaporation of the extract.
Příklad 2Example 2
1-(3-/2-Chlor-6,1]-čihydrodibenzo(b,e)thiepin-11-yl/propyl)-4-(2-hydroxyethyl)piperazin1- (3- / 2-Chloro-6,1) -hydrodibenzo (b, e) thiepin-11-yl / propyl) -4- (2-hydroxyethyl) piperazine
Směs 13,5 g (E)-í-(3-/2-chlor-6,11-dihydrodibenzo(b,e)thiepin-11-yliden/propyl)-4-(2-hydroxyethyl)piperazinu, 60 ml kyseliny octové, 42 ml 55% kyseliny jodovodíkové a 5,6 g červeného fosforu se míchá a vaří 5 h pod zpětným chladičem. Po stání přes noc se zfiltruje, filtrát se zředí vodou, zalkalizuje se 20% roztokem hydroxidu sodného a extrahuje se chloroformem. Extrakt se promyjevodou a odpaří za sníženého tlaku.A mixture of 13.5 g of (E) -1- (3- / 2-chloro-6,11-dihydrodibenzo (b, e) thiepin-11-ylidene / propyl) -4- (2-hydroxyethyl) piperazine, 60 ml of acid acetic acid, 42 ml of 55% hydroiodic acid and 5.6 g of red phosphorus were stirred and refluxed for 5 h. After standing overnight, it is filtered, the filtrate is diluted with water, basified with 20% sodium hydroxide solution and extracted with chloroform. The extract was washed with water and evaporated under reduced pressure.
K zbytku se přidá horký roztok 8,0 g kyseliny maleinové v 45 ml ethanolu a po stání přes noc se sraženina maleinátu odsaje a překrystaluje z vody.A hot solution of 8.0 g of maleic acid in 45 ml of ethanol was added to the residue, and after standing overnight the maleate precipitate was filtered off with suction and recrystallized from water.
Získá se produkt (nehomogenní) tající při 162 až 164 °C. Rozloží se vodným amoniakem, base se isoluje extrakcí chloroformem a chromatografuje se na koloně 150 g neutrálního kysličníku hlinitého (aktivita II). Elucí benzenem se získá 4,5 g (33 %) homogenní base, která poskytuje 4,8 g bis(hyčrogenmaleinátu), t.t. 182 až 184 °C (80% vodný ethanol).The product (inhomogeneous) melting at 162-164 ° C is obtained. Quench with aqueous ammonia, isolate the base with chloroform extraction and chromatograph on a 150 g neutral alumina column (activity II). Elution with benzene gave 4.5 g (33%) of a homogeneous base, yielding 4.8 g of bis (hydrogen maleate), m.p. 182 DEG-184 DEG C. (80% aqueous ethanol).
Výchozí aminoalkohol je látkou novou, kterou lze připravit déle uvedeným postupem ze známého 2-chlordibenzo(b,e)thiepin-11(6H)-onu (Rajšner M. et al., Česk. Farm. 11. 45', i26£):The starting aminoalcohol is a novel compound which can be prepared as described above from the known 2-chlorodibenzo (b, e) thiepin-11 (6H) -one (Rajner M. et al., Czech Farm. 11. 45 ', 1226). :
&&
Reakcí 4,7 g hořčíku s 25,0 g cyklopropylbromidu (Meek J. S., Osuga D. Τ., Org. Syn., Coll. Vol. 5 '26, 1973) ve 100 ml tetrehydrofuranu se připraví roztok Grignardova činidla ‘ (viz Rejšner M. et al., Collect. Czech. Chem. Commun. 44. 2536, 1979). Roztok činidla se ochladí na teplotu místnosti a za míchání se k němu po kapkách přidá během 1 h teplý roztok 25,9 g 2-chlordibenzo(b,e)thiepin-11(6H)-onu ve 100 ml tetrehydrofuranu. Směs se vaří 1 h pod zpětným chladičem, ochladí se ledovou lázní a za míchání se rozloží pomalým přidáním 135 ml nasyceného roztoku chloridu amonného. Směs se extrahuje etherem, extrakt. ' se promyje nasyceným roztokem chloridu sodného, vysuší se síranem sodným a odpaří.A solution of Grignard's reagent is prepared by reacting 4.7 g of magnesium with 25.0 g of cyclopropyl bromide (Meek JS, Osuga D. Τ., Org. Syn., Coll. Vol. 5 '26, 1973) in 100 ml of tetrehydrofuran (see Register). M. et al., Collect. Czech. Chem. Commun. 44, 2536, 1979). The reagent solution was cooled to room temperature and a warm solution of 25.9 g of 2-chlorodibenzo (b, e) thiepin-11 (6H) -one in 100 ml of tetrahydrofuran was added dropwise over 1 h with stirring. The mixture was refluxed for 1 h, cooled in an ice bath, and quenched with slow addition of 135 mL of saturated ammonium chloride solution with stirring. The mixture was extracted with ether, extract. It is washed with saturated sodium chloride solution, dried over sodium sulphate and evaporated.
Stáním odparku přes noc proběhne krystalizace a získá se 26,7 g (92 %) krystalického 2-chlor-:11-cyklopropyl-6,11-dihydrodibenzo(b,e)thiepin-11-olu tajícího při 124 až 127 °C. Rekrystalizací vzorku ze směsi benzenu a patroletheru se získá analyticky čistá látka tající při 129 ež 131 °C.Upon standing the residue crystallized overnight to give 26.7 g (92%) of crystalline 2-chloro-: 11-cyclopropyl-6,11-dihydrodibenzo (b, e) thiepin-11-ol melting at 124-127 ° C. Recrystallization of the sample from a mixture of benzene and patrol ether gave an analytically pure material, m.p. 129-131 ° C.
£ míchanému roztoku 10,0 g předešlého alkoholu ve 170 ml kyseliny octové se během 30 minut při 10 až 15 °C přikape 85 ml 15% roztoku bromovodíku v kyselině octové. Směs se ponechá 24 h při teplotě místnosti, zfiltruje se s aktivním uhlím, filtrát se zředí 200 ml vody a extrahuje se benzenem. Extrakt se promyje vodou,.vysuší se síranem hořečnatým a odpaří. Zbytek krystaluje po zředění cyklohexanem. Získá se 9,0 g (75 %) surového (£)-11-(3-brompropyliden)-2-chlor-6,11-dihydrodlbenzo(b,e)thiepinu, který se překryatalůje ze směsi cyklohexanu a hexanu a získá se potom v čistém stavu jako tající při 109 až 111 °C.A stirred solution of 10.0 g of the preceding alcohol in 170 ml of acetic acid was added dropwise over 30 minutes at 10-15 ° C with 85 ml of a 15% solution of hydrogen bromide in acetic acid. The mixture is left at room temperature for 24 h, filtered with charcoal, the filtrate is diluted with 200 ml of water and extracted with benzene. The extract was washed with water, dried (MgSO4) and evaporated. The residue crystallizes upon dilution with cyclohexane. 9.0 g (75%) of crude (E) -11- (3-bromopropyl) -2-chloro-6,11-dihydrodibenzo (b, e) thiepine are obtained, which is recrystallized from a mixture of cyclohexane and hexane to give then in the pure state as melting at 109-111 ° C.
Směs 5,0 g předešlého bromderivátu 6,0 g l-(2-hydroxyetyl)piperazinu a 10 ml chloroformu se míchá a vaří 3 h pod spětným chladičem. Směs se potom zředí 50 ml chloroformu, zfiltruje se s aktivním uhlím, filtrát se promyje vodou a potom se extrahuje roztokem 10 ml kyseliny chlorovodíková v 60 ml vody. Vodné vrstva se zfiltruje e aktivním uhlím, filtrát se zalkalisuje vodným amoniakem a produkt se extrahuje dichlormethanem. Extrakt se vysuší uhličitanem draselným a odpaří. Olejovitý zbytek se rozpustí v 50 ml ethanolu a rostok sa neutralizuje roztokem vypočteného množství kyseliny maleinové v ethanolu. Stání a chlazení vede ke krystalizaci, kterou se získá 5,2 g (59 %)bis(hydrogenmaleinátu) (S)-1-(3-/2_chlor-6,11-dihydrodibsnzo(b,e)thispin-11-yllden/propyl)-4-(2-hydroxyethyl)piperat! Zinu, t.t. 163 až 165 °C. krystalizaci ze směsi ethanolu a etheru ss získá čistá s&l tající při 165 až 166 °C. Rozkladem táto soli vodným amoniakem a extrakcí chloroformem se získá base tající při 121 až 122 °C (benzen-petrolether). Neutralizací táto base Iqrselinou methansulfonovou v ethanolu lze připravit krystalicky dimethanaulfonát tající při 206 až 208 °C (ethanol-ether).A mixture of 5.0 g of the above bromo derivative, 6.0 g of 1- (2-hydroxyethyl) piperazine and 10 ml of chloroform was stirred and refluxed for 3 hours. The mixture is then diluted with 50 ml of chloroform, filtered with charcoal, the filtrate is washed with water and then extracted with a solution of 10 ml of hydrochloric acid in 60 ml of water. The aqueous layer was filtered with charcoal, the filtrate was basified with aqueous ammonia, and the product was extracted with dichloromethane. The extract was dried over potassium carbonate and evaporated. The oily residue is dissolved in 50 ml of ethanol and the residue is neutralized with a solution of a calculated amount of maleic acid in ethanol. Standing and cooling led to crystallization, yielding 5.2 g (59%) of bis (hydrogen maleate) (S) -1- (3- (2-chloro-6,11-dihydrodibenzo) (b, e) thispin-11-ylldene) propyl) -4- (2-hydroxyethyl) piperazine; Zine, m.p. Mp 163-165 ° C. crystallization from a mixture of ethanol and ether ss gives pure melting at 165-166 ° C. Decomposition of this salt with aqueous ammonia and extraction with chloroform gave a base melting at 121-122 ° C (benzene-petroleum ether). By neutralizing this base with methanesulfonic acid in ethanol, a dimethanesulfonate melting at 206 DEG-208 DEG C. (ethanol-ether) can be obtained.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS76484A CS236549B1 (en) | 1984-02-02 | 1984-02-02 | Piperazinoalkanoles of dibenzo (b,e)thiepine series and their salts with maleic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS76484A CS236549B1 (en) | 1984-02-02 | 1984-02-02 | Piperazinoalkanoles of dibenzo (b,e)thiepine series and their salts with maleic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CS236549B1 true CS236549B1 (en) | 1985-05-15 |
Family
ID=5340368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS76484A CS236549B1 (en) | 1984-02-02 | 1984-02-02 | Piperazinoalkanoles of dibenzo (b,e)thiepine series and their salts with maleic acid |
Country Status (1)
Country | Link |
---|---|
CS (1) | CS236549B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732459B2 (en) | 2002-11-13 | 2010-06-08 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use therefor |
US8653096B2 (en) | 2001-11-21 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
-
1984
- 1984-02-02 CS CS76484A patent/CS236549B1/en unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8653096B2 (en) | 2001-11-21 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
US9663537B2 (en) | 2001-11-21 | 2017-05-30 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use |
US7732459B2 (en) | 2002-11-13 | 2010-06-08 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use therefor |
US7977350B2 (en) | 2002-11-13 | 2011-07-12 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use therefor |
US8394817B2 (en) | 2002-11-13 | 2013-03-12 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use therefor |
US9334283B2 (en) | 2002-11-13 | 2016-05-10 | Millennium Pharmaceuticals, Inc. | CCR1 antagonists and methods of use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2614406C2 (en) | ||
US3420851A (en) | Novel dibenzoxepines | |
DE2111071B2 (en) | 4- (1-Alkyl-4-piperidylidene) -4H-benzo [43] cyclohepta [1,2-b] thiophen-10 (9H) -ones or -9 (IOH) -ones, processes for their preparation and these Medicines containing compounds | |
CH642361A5 (en) | 4-ANILINOQUINAZOLINE DERIVATIVES, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM. | |
DE1138779B (en) | Process for the preparation of 10- (aminoalkyl) -trifluoromethyl-phenthiazine derivatives substituted in the amino group. | |
DE1795183B1 (en) | 5,11-dihydro-6H-pyrido [2,3-b] [1,4] benzodiazepin-6-one derivatives and drugs | |
CH395136A (en) | Process for the production of xanthenes or thiaxanthenes | |
DE2011806A1 (en) | New Trieyclisehe Compounds | |
DE1470157A1 (en) | Process for the preparation of substituted thioxanthenesulfonamides and their acid addition salts | |
GB1569039A (en) | Derivatives of 10,11-dihydrobenzo(4,5)-cyclohepta(1,2-b)-pyrazolo(4,3-e)-pyridine-5(1h)one | |
DD238792A5 (en) | PROCESS FOR THE PREPARATION OF BENZOTHIOPHENE DERIVATIVES | |
CS236549B1 (en) | Piperazinoalkanoles of dibenzo (b,e)thiepine series and their salts with maleic acid | |
O'BRIEN et al. | Amino derivatives of Kojic acid | |
DE2117358C3 (en) | 4'-aminomethyl-spiro square bracket on dibenzo square bracket on a, square bracket on cycloheptadi- (or tri-) en-5,2 '- (1 \ 3'-dioxolane) square bracket on derivatives, method for their Manufacture and medicinal products containing these compounds | |
US3998965A (en) | 4-Aminoalkyl-4-cyano-4-phenyl-butanoic acid esters | |
JPS6038383B2 (en) | Novel 1-[3-(3,4,5-trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine derivatives and their production method | |
US3557098A (en) | Substituted-7,12-dihydropleiadene derivatives | |
US4035497A (en) | Butanoic and butenoic acid morpholides | |
AT215424B (en) | Process for the production of xanthenes or thiaxanthenes | |
CS249455B1 (en) | N-substituted 2-chloro-7-fluoro-10-piperazino-10,11-dihydrodibenzo(b,f)thiepines and their salts and method of their preparation | |
US3466290A (en) | 9,10-dihydro-4h-benzo(4,5)cyclohepta(1,2-b)thiophene ethers | |
DE1695682A1 (en) | New heterocyclic compounds and processes for their preparation | |
DE2333262A1 (en) | PROCESS FOR THE MANUFACTURING OF NEW 1,1A, 6,10B-TETRAHYDRO-1,6-METHANO-DIBENZO SQUARE CLAMP ON A, SQUARE BRACKET FOR -CYCLOPROPA SQUARE BRACKET FOR CYCLOHEPTEN DERIVATIVES | |
US4029799A (en) | Certain analgesically active substituted benzyl pyridine compounds | |
AT212318B (en) | Process for the production of new phenthiazine derivatives |